CLAIMS

1. The use of an immunogenic composition comprising a recombinant RSV (Respiratory syncytial virus) antigen comprising a soluble F protein comprising at least one modification that stabilizes the prefusion conformation of the F protein, and an adjuvant, in the manufacture of a medicament for raising an immune response to RSV in a human in co-administration with an immunogenic composition comprising at least one glycoconjugate from each of *S. pneumoniae* (*Streptococcus pneumoniae*) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F.

2. The use of an immunogenic composition comprising a recombinant RSV (Respiratory syncytial virus) antigen comprising a soluble F protein comprising at least one modification that stabilizes the prefusion conformation of the F protein, in the manufacture of a medicament for raising an immune response to RSV in a human, wherein an immunogenic composition comprising at least one glycoconjugate from each of *S. pneumoniae* (*Streptococcus pneumoniae*) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F is co-administered.

3. The use of an immunogenic composition comprising at least one glycoconjugate from each of *S. pneumoniae* (*Streptococcus pneumoniae*) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, in the manufacture of a medicament for raising an immune response to *S. pneumoniae* in a human, wherein an immunogenic composition comprising a recombinant RSV antigen comprising a soluble F protein comprising at least one modification that stabilizes the prefusion conformation of the F protein is co-administered.

4. The use of an immunogenic composition comprising a recombinant RSV (Respiratory syncytial virus) antigen comprising a soluble F protein comprising at least one modification that stabilizes the prefusion conformation of the F protein, and an immunogenic composition comprising at least one glycoconjugate from each of *S. pneumoniae* (*Streptococcus pneumoniae*) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, in the manufacture of

a medicament for raising an immune response to RSV and *S. pneumoniae* in a human comprising co-administering to the human said immunogenic compositions.

5. The use of the immunogenic compositions of claims 1-4, wherein the at least one modification is selected from the group consisting of:

i) an addition of an amino acid sequence comprising a heterologous trimerization domain;

ii) a deletion of at least one furin cleavage site;

iii) a deletion of at least one non-furin cleavage site;

iv) a deletion of one or more amino acids of the pep27 domain; and

v) at least one substitution or addition of a hydrophilic amino acid in a hydrophobic domain of the F protein extracellular domain.

6. The use of the immunogenic compositions of claims 1-4, wherein the at least one modification comprises the addition of an amino acid sequence comprising a heterologous trimerization domain.

7. The use of the immunogenic compositions of claims 1-4, wherein the recombinant RSV antigen comprises an F2 domain and an F1 domain of an RSV F protein with no intervening furin cleavage site wherein the polypeptide further comprises a heterologous trimerization domain positioned C-terminal to the F_1 domain.

8. The use of the immunogenic compositions of claims 1-4, wherein the recombinant RSV antigen comprises a pre-fusion RSV F polypeptide having an HRA region (residues 137-239 of reference RSV F protein of SEQ ID NO:1) and a DIII region (residues 51-98 and 206-308 of reference RSV F protein of SEQ ID NO:1), wherein a cysteine residue is introduced into the HRA region and a cysteine residue is introduced into the DIII region, and a disulfide bond is formed between the introduced cysteine residue in the HRA region and the introduced cysteine residue in the DIII region that prevents a post-fusion HRA-HRB six-helix bundle from forming.

9. The use of the immunogenic compositions of claims 1-4, wherein the immunogenic composition that comprises a recombinant RSV antigen further comprises an adjuvant.

10. The use of the immunogenic composition of claim 9, wherein the adjuvant comprises MPL and QS-21.

11. The use of the immunogenic composition of claim 10, wherein the MPL is present in the immunogenic composition in an amount of about 25 µg and the QS-21 is present in the immunogenic composition in an amount of about 25 µg.

12. The use of the immunogenic compositions of claims 1-4, wherein the human is 60 years old and above.

13. The use of the immunogenic compositions of claims 1-4, wherein said glycoconjugates are individually conjugated to CRM197.

14. The use of the immunogenic compositions of claims 1-4, wherein the immunogenic composition comprising at least one glycoconjugate further comprises an adjuvant.

15. The use of the immunogenic composition of claim 14, wherein the adjuvant is an aluminum salt selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide.